Jasper Therapeutics
JSPR
21 hedge funds and large institutions have $9.6M invested in Jasper Therapeutics in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 3 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.81% less ownership
Funds ownership: 55.43% → 54.62% (-0.81%)
5% less funds holding
Funds holding: 22 → 21 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
34% less capital inflows, than outflows
Capital inflows: $215K | Capital outflows: $323K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fernwood Investment Management
Quincy,
Massachusetts
|
+$106K |
| 2 |
Renaissance Technologies
New York
|
+$24.7K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$23.1K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$22.1K |
| 5 |
Millennium Management
New York
|
+$19.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$316K |
| 2 |
Forefront Analytics
West Conshohocken,
Pennsylvania
|
-$3.82K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$2K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
-$602 |
| 5 |
Tower Research Capital (TRC)
New York
|
-$602 |
JSPR Hedge Fund Activity: Q4 2022 in Review
21 of the 6,244 institutional investors tracked by Wall St. Rank reported a position in Jasper Therapeutics (JSPR) for Q4 2022, worth a combined $9.6M — down 39% from $15.7M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of JSPR and 2 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 6 added.
The largest buyer was Fernwood Investment Management, adding an estimated $106K. The largest seller was Sectoral Asset Management, exiting entirely with an estimated $316K sold.
- 21 institutional investors held Jasper Therapeutics (JSPR) as of Q4 2022, down from 22 in Q3 2022.
- Funds reported $9.6M of Jasper Therapeutics stock for Q4 2022, down 39% quarter-over-quarter.
- 2 funds opened new Jasper Therapeutics positions in Q4 2022 and 3 closed out, a net change of -1 holder.
- The largest Jasper Therapeutics buyer in Q4 2022 was Fernwood Investment Management, an estimated $106K added.
- The largest Jasper Therapeutics seller in Q4 2022 was Sectoral Asset Management, an estimated $316K sold.
Based on aggregated 13F filings for Q4 2022.